TD Cowen analyst Steve Scala maintained a Hold rating on Sanofi (SNY – Research Report) today. The company’s shares closed last Friday at $49.28.
According to TipRanks, Scala is a 4-star analyst with an average return of 9.3% and a 66.43% success rate. Scala covers the Healthcare sector, focusing on stocks such as Novartis, AstraZeneca, and Eli Lilly & Co.
Sanofi has an analyst consensus of Hold.
The company has a one-year high of $54.08 and a one-year low of $41.37. Currently, Sanofi has an average volume of 1.99M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sanofi (SNY) Company Description:
Founded in 1973, Sanofi is a France-based leading global healthcare company, which provides therapeutic solutions worldwide. It operates through business units including Pharmaceuticals (comprised of General Medicines and Speciality Care), Consumer Healthcare, and Vaccines.
Read More on SNY:
- BofA upgrades Novavax to Neutral on ‘best outcome’ Sanofi pact
- H.C. Wainwright reiterates Buy rating on Novavax after ‘landmark’ Sanofi deal
- NVAX Earnings: Novavax Soars After Stellar Growth in Revenue, Sanofi Deal Boost
- Novavax, Sanofi enter co-exclusive COVID-19 vaccine licensing agreement
- Royalty Pharma to acquire royalty interest in Sanofi’s frexalimab
